Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. GenLabMeds
WARNING LETTER
•GenLabMeds•August 31, 2025

GenLabMeds – FDA Warning Letter, Aug 31, 2025

Record Details

GenLabMeds received a warning letter from the FDA on September 9, 2025, following a review of their website in August 2025. The FDA identified significant regulatory violations concerning the company"s marketing of compounded drug products, including retatrutide, semaglutide, and tirzepatide. The primary issues include the sale of unapproved new drugs and misbranded drugs, violating sections 505(a), 502(f)(1), 301(a), and 301(d) of the Federal Food, Drug, and Cosmetic Act (FDCA).

The compounded retatrutide products do not meet the conditions for exemptions under sections 503A and 503B of the FDCA. Specifically, retatrutide is not covered by a United States Pharmacopeia or National Formulary monograph, is not an FDA-approved drug component, and is absent from the 503A and 503B bulks lists. Consequently, these products lack FDA approval and adequate labeling, rendering them misbranded.

Furthermore, the website"s claims about the compounded products are deemed false or misleading, suggesting equivalence to FDA-approved drugs, which they are not. This misrepresentation results in additional violations under sections 502(a) and 502(bb) of the FDCA.

The FDA requires GenLabMeds to cease the introduction of these unapproved and misbranded products into interstate commerce. The company must address these violations promptly to comply with federal regulations and avoid further enforcement actions.

Company
GenLabMeds
Inspection date
August 31, 2025
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • George Tidmarsh (Director)
View Company Profile

ID · 5feefd08-29ae-4cb8-95e4-775ea91b9570

Violation Codes10
FD&C Act 505(a)FD&C Act 502(f)(1)FD&C Act 301(a)FD&C Act 301(d)21.U.S.C. 355(a)21 U.S.C. 352(f)(1)21 U.S.C. 331(d)FD&C Act 502(a)FD&C Act 502(b)21 U.S.C. 352(a)

Full citation text and observation details available on the Dashboard.

Other documents for GenLabMeds
  • WARNING_LETTER - 2025-08-01August 1, 2025

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore GenLabMeds
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.